Results 41 to 50 of about 25,335 (131)

Associations of Fire Smoke and Other Pollutants With Incident Rheumatoid Arthritis and Rheumatoid Arthritis–Associated Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to determine whether pollutants such as fire smoke–related particulate matter <2.5 μm (PM2.5) are associated with incident rheumatoid arthritis (RA) and RA‐associated interstitial lung disease (RA‐ILD). Methods This patient–control study used Veterans Affairs (VA) data from October 1, 2009, to December 31, 2018.
Vanessa L. Kronzer, Yangyuna Yang, Punyasha Roul, James L. Crooks, Cynthia S. Crowson, John M. Davis III, Jeffrey A. Sparks, Jeffrey R. Pierce, Katelyn O'Dell, Brian C. Sauer, Grant W. Cannon, Joshua F. Baker, Ted R. Mikuls, Bryant R. England   +13 more
wiley   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal, Hunger, Matthias, Jugl, Steffen M., Karabis, Andreas, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Nash, Peter, Thom, Howard   +8 more
core   +2 more sources

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis:a non-randomised pragmatic study [PDF]

, 2015
To determine the outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis (RA)
Abdelhamid, Arnett, Bond, Bowling, Briggs, Briggs, Brooks, Bruce, Cooper, Curtis, Dolan, Drummond, Fenwick, Gruen, Heyse, Hill, Hill, Hill, Koksvik, Leary, Little, Manca, Ndosi, Ndosi, NHS, NICE, Oliver, Primdahl, Royston, Sach, Sach, Symmons, Sørensen, Tijhuis, Van den Hout, Van Eijk-Hustings   +35 more
core   +1 more source

Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA)–associated anticitrullinated protein antibodies (ACPAs) target various antigens by binding short citrulline amino acid motifs, resulting in heterogeneous ACPA profiles among patients. Here we analyzed ACPA patterns by recognized citrulline motifs in relation to the RA risk factors HLA‐DRB1 shared epitope (SE) alleles
Linda Mathsson Alm, Helga Westerlind, Isabel Gehring, Monika Hansson, Nasim Ghasemzadeh, Jessica Rojas‐Restrepo, Saedis Saevarsdottir, Joe Sexton, Siri Lillegraven, Espen Haavardsholm, Bente Glintborg, Hilde Berner Hammer, Tore K. Kvien, Merete Lund Hetland, Leonid Padyukov, Swedish Rheumatology Quality Register Biobank Study Group (SRQb), The Danish Rheumatologic Biobank Study Group, Johan Askling, Caroline Grönwall   +18 more
wiley   +1 more source

Future therapeutic targets in rheumatoid arthritis? [PDF]

, 2017
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment.
A Balanescu, A Bilancio, A Del Prete, A Maas, AB Avci, AB Satterthwaite, AD Cook, AG Semb, AJ Fleetwood, AJ Fleetwood, AJ Mohamed, AL Bell, AL Cornish, AM Condliffe, AR Pettit, AW Lieshout van, B Ludewig, BF Nashed, BJ Jenkins, BZ Li, C Baerwald, C Meune, C Rommel, C Schindler, C Voigtlander, CA Martin, CJ Heijnen, CM Hilkens, CV Brenol, D Heijde van der, DH Solomon, DJ Rawlings, DL Bellinger, DM Nance, DS Lim, DT Patton, E Banham-Hall, E Clayton, E Feist, E Hirsch, E Martin, E Thomas, EB Lee, EC Tsark, EK Evans, F Berenbaum, F Bussolino, F Ramadani, FA Koopman, FA Koopman, FM Foster, G Hansen, GM Bell, GR Burmester, GR Burmester, H Evrengul, H Wang, Iain B. McInnes, IC Eijk van, IJ Elenkov, IK Campbell, J Askling, J Jang, J Kremer, JA Avina-Zubieta, JA Hamilton, JC Barrientos, JE Park, JM Kremer, JM Waldburger, JS Rawlings, JS Smolen, K Imada, K Okkenhaug, K Okkenhaug, K Okkenhaug, K Pavelka, K Reif, K Shuai, K Thiele, K Yamaoka, KL Winthrop, KP MacDonald, KS Nair, L Conti, L Jansson, L Senolt, L Zhang, L Zou, LC Cantley, LG Schipper, LJ Courtright, LV Borovikova, M Camps, M Dougados, M Field, M Gilliet, M Pesu, M Rosas-Ballina, M Skoberne, M Skoberne, M Soubrier, M Westman, MA Maanen van, MA Maanen van, MA Maanen van, MB Torchinsky, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Genovese, MC Lebre, MC Lebre, MG Roncarolo, MJ Peters, MS Ahmed, MS Thomas, N Krishnamoorthy, N Sato, NJ Gullick, P Geborek, P Norman, P Sujobert, PC Heinrich, PC Taylor, Q Yang, R Fleischmann, R Fleischmann, RA Maldonado, RF Vollenhoven van, RH Straub, RM Buijs, RM Steinman, RM Steinman, S Hayer, S Kleinau, S Mukhopadhyay, S Mukhopadhyay, S Somersan, S Tsukada, SA Provan, ST Jou, T Leizer, T Li, Tommy Tsang Cheung, TR Radstake, WJ Jonge de, WN Khan, Y Ren, Y Xu, YP Goekoop-Ruiterman, Z Li, Z Pan   +154 more
core   +1 more source

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

Arthritis &Rheumatology, EarlyView.
Objective This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk. Methods We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis.
Achille Marino, Maria Vittoria Cicinelli, Elisabetta Miserocchi, Stefania Costi, Francesco Baldo, Maurizio Virgilio Gattinara, Pierluigi Scandale, Scott D. Smith, Debra A. Goldstein, Dina Baddar, Terese K. A. Gerges, Timothy M. Janetos, Matilde Ruiz‐Cruz, Kazuichi Maruyama, Massimiliano Serafino, Paola Camicione, Vishali Gupta, Radgonde Amer, Emilio M. Dodds, Sebastian Inchauspe, Marion R. Munk, Ester Carreño, Soon‐Phaik Chee, Aniruddha Agarwal, Ariel Schlaen, Ramiro A. Gómez, Cristobal A. Couto, Moncef Khairallah, Piergiorgio Neri, Cecilia B. Chighizola, Roberto F. Caporali, Francesco Pichi   +31 more
wiley   +1 more source

Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? [PDF]

, 2017
No abstract ...
McInnes, Iain B., Porter, Duncan, Siebert, Stefan   +2 more
core   +1 more source

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population ...
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L. Hyrich, Florenzo Iannone, Tore K. Kvien, Burkhard F. Leeb, Dan Nordström, Lucia Otero‐Varela, Karel Pavelka, Manuel Pombo‐Suarez, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Sella A. Provan, Anja Strangfeld, Trokovic Nina, Jakub Zavada, Lianne Kearsley‐Fleet, Delphine S. Courvoisier, Axel Finckh, Kim Lauper   +28 more
wiley   +1 more source

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source